Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 10639284 Immunomodulator compounds

Patent 10639284 was granted and assigned to ChemoCentryx on May, 2020 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
0
Current Assignee
ChemoCentryx
ChemoCentryx
0
Date Filed
June 26, 2017
0
Date of Patent
May 5, 2020
0
Patent Applicant
ChemoCentryx
ChemoCentryx
0
Patent Application Number
15633569
0
Patent Citations Received
‌
US Patent 12083118 Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
0
‌
US Patent 11866429 Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases
0
‌
US Patent 11872217 Indanes as PD-L1 inhibitors
0
‌
US Patent 12059470 Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof
0
‌
US Patent 11059834 Macrocyclic immunomodulators
‌
US Patent 11691985 Macrocyclic immunomodulators
0
‌
US Patent 11708326 Immunomodulator compounds
0
‌
US Patent 11759458 Indane-amines as PD-L1 antagonists
‌
US Patent 11426364 Immunomodulator compounds
‌
US Patent 11833209 Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
10639284
0
Patent Primary Examiner
‌
Patricia L Morris
0

Find more entities like US Patent 10639284 Immunomodulator compounds

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.